Court Orders Scientific Misconduct Labels Removed From Fisher's Work

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

WASHINGTON--Bernard Fisher, MD, Distinguished Service Professor of Surgery, University of Pittsburgh, has won a court order requiring that scientific misconduct labels be removed from citations of his papers in federal databases (Cancerlit and Medline).

WASHINGTON--Bernard Fisher, MD, Distinguished Service Professorof Surgery, University of Pittsburgh, has won a court order requiringthat scientific misconduct labels be removed from citations ofhis papers in federal databases (Cancerlit and Medline).

The labels were added at the insistence of the Office of ResearchIntegrity after last year's revelations of misconduct by a Montrealparticipant in NSABP trials headed by Dr. Fisher. The government,through faxes sent to distributors of the databases, will alsoapologize for the labels, stating that Dr. Fisher's own researchhas never been found to be at fault.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content